Table 1.
Laboratory, Electrocardiographic, and Echocardiography Parameters in Male Patients With and Without Inflammation
| Parameter | Male patients with inflammatory diseases (n=22) | Male patients without inflammation (controls) (n=10) | ||
|---|---|---|---|---|
| Before therapeutic intervention (PRE) | After therapeutic intervention (POST) | P value | ||
| CRP, mg/dL (r.v. <0.5) | 10.9 (7.9–23.2) | 1.6 (0.4–2.5) | <0.0001* | 0.18 (0.1–0.4) |
| Interleukin‐6, pg/mL (r.v. 0.49–1.25) | 14.0 (10.1–53.2) | 2.8 (0.8–12.4) | <0.0001* | 0.3 (0.1–7.2) |
| Interleukin‐1, pg/mL (r.v. 0.08–0.29) | 0.27 (0.2–0.4) | 0.26 (0.2–0.4) | 0.30 | 0.05 (0.0–0.1) |
| Tumor necrosis factor‐α, pg/mL (r.v. 0.60–3.24) | 0.75 (0.6–0.8) | 0.75 (0.6–0.9) | 0.68 | 0.42 (0.4–0.8) |
| Interleukin‐10, pg/mL (r.v. 0–3.60) | 0.56 (0.5–0.8) | 0.55 (0.4–1.6) | 0.59 | 0.46 (0.4–0.6) |
| Total testosterone, ng/mL | 1.10 (0.7–1.5) | 1.90 (1.5–2.6) | <0.001* | 2.22 (1.4–3.3) |
| Free testosterone, ng/mL | 0.021 (0.009–0.027) | 0.031 (0.019–0.043) | <0.001* | 0.044 (0.024–0.05) |
| Bioavailable testosterone, ng/mL | 0.50 (0.2–0.6) | 0.76 (0.5–1.0) | <0.001* | 1.02 (0.6–1.2) |
| SHBG, nmol/L | 56.8 (23.1–48.3) | 40.2 (30.0–56.2) | 0.46 | 39.8 (34.4–53.5) |
| 17‐β estradiol, pg/mL | 37.9 (10.8–103.4) | 15.5 (10.0–39.8) | 0.0052* | 16.7 (10.0–27.2) |
| Progesterone, ng/mL | 0.10 (0.1–0.1) | 0.10 (0.1–0.3) | 0.46 | 0.10 (0.1–0.2) |
| FSH, mIU/mL | 11.0 (4.8–19.0) | 10.2 (5.1–22.5) | 0.23 | 6.8 (4.9–14.6) |
| LH, mIU/mL | 6.9 (0.5–28.0) | 6.9 (1.9–26.7) | 0.54 | 4.0 (1.0–21.0) |
| QT, ms | 394 (361–423) | 398 (370–420) | 0.78 | 406 (368–421) |
| RR, ms | 758 (655–840) | 833 (731–992) | <0.001* | 995 (868–1074) |
| Heart rate, bpm | 79.0 (71.8–91.8) | 72.5 (60.0–82.0) | <0.001* | 60.6 (56.3–71.1) |
| QTc‐Bazett, ms | 472.0 (436–499) | 444.5 (426–452) | <0.001* | 417.0 (397–423) |
| Patients with prolonged QTc ‡ , n (%) | 12 (55) | 2 (9) | 0.004* | 0 (0) |
| Patients with QTc >500 ms, n (%) | 5 (23) | 1 (5) | 0.13 | 0 (0) |
| QTc‐Fridericia, ms | 436.5 (417–474) | 423.5 (407–443) | 0.0033* | 408.0 (386–422) |
| Patients with prolonged QTc ‡ , n (%) | 6 (27) | 1 (5) | 0.09 | 0 (0) |
| Patients with QTc >500 ms, n (%) | 2 (9) | 1 (5) | 1.0 | 0 (0) |
| QTc‐Hodges, ms | 436.5 (413–466) | 420.5 (406–439) | 0.0037* | 411.0 (384–422) |
| Patients with prolonged QTc * , n (%) | 5 (23) | 1 (5) | 0.13 | 0 (0) |
| Patients with QTc >500 ms, n (%) | 1 (5) | 1 (5) | 1.0 | 0 (0) |
Cytokine level ranges measured in an internal reference group of healthy controls. Therapeutic interventions resulted in a >75% CRP decrease when compared with the baseline. Data are expressed as median (interquartile range) or frequency (percentage). Differences in continue variables were evaluated by the 2‐tailed Wilcoxon matched pairs test. Difference in categorical variables were evaluated by McNemar test. CRP indicates C‐reactive protein; FSH, follicle‐stimulating hormone; LH, luteinizing hormone; QTc, heart rate–corrected QT interval; r.v., reference values; and SHBG, sex hormone–binding globulin.
Statistically‐significant p‐values (<0.05).
QTc >470 ms.